Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 5/20 | 0.39 |
| ▸ | CTSG | P08311 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 4/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 9/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2164147 | 0.88 | ELANE (0.43) | ELANECTSGTHRBEPHX2SOAT1 | |
| SCHEMBL12402099 | 0.82 | THRB (0.40) | THRBEPHX2SOAT1THRA | |
| SCHEMBL2903786 | 0.71 | THRB (0.40) | THRBEPHX2SOAT1THRA | |
| SCHEMBL2904057 | 0.71 | KDM4E (0.43) | THRBEPHX2 | |
| SCHEMBL2906943 | 0.71 | KDM4E (0.43) | THRBEPHX2 | |
| SCHEMBL12402087 | 0.70 | SERPINE1 (0.43) | ELANECTSGTHRBEPHX2SOAT1 | |
| SCHEMBL10894850 | 0.69 | THRB (0.39) | THRBSOAT1THRA | |
| SCHEMBL2164075 | 0.68 | ELANE (0.39) | ELANECTSGTHRBSOAT1 | |
| SCHEMBL2166798 | 0.67 | LMNA (0.41) | ELANECTSG | |
| SCHEMBL12402106 | 0.66 | SERPINE1 (0.39) | ELANECTSGTHRBEPHX2SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8277695-B2 | Reversibly thermochromic compositions | BASF SE (DE) | 2012-10-02 | — | — | US | disclosed |
| EP-2032657-B1 | REVERSIBLY THERMOCHROMIC COMPOSITIONS | BASF SE (DE) | 2011-08-10 | — | — | EP | disclosed |
| US-20110180767-A1 | Reversibly thermochromic compositions | CIBA CORPORATION | 2011-07-28 | — | — | US | disclosed |
| EP-2032657-A2 | REVERSIBLY THERMOCHROMIC COMPOSITIONS | Ciba Holding Inc. (CH) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007147847-A2 | REVERSIBLY THERMOCHROMIC COMPOSITIONS | CIBA HOLDING INC. (CH) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110180767-A1 | Reversibly thermochromic compositions | C1R, C3AR1, C9 | ELANE 4215/4885CTSG 4051/4885THRB 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.